1. Home
  2. DBVT vs ZVRA Comparison

DBVT vs ZVRA Comparison

Compare DBVT & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DBV Technologies S.A.

DBVT

DBV Technologies S.A.

N/A

Current Price

$9.02

Market Cap

692.2M

Sector

Health Care

ML Signal

N/A

Logo Zevra Therapeutics Inc.

ZVRA

Zevra Therapeutics Inc.

N/A

Current Price

$8.73

Market Cap

664.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DBVT
ZVRA
Founded
2002
2006
Country
France
United States
Employees
90
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
692.2M
664.7M
IPO Year
2014
2015

Fundamental Metrics

Financial Performance
Metric
DBVT
ZVRA
Price
$9.02
$8.73
Analyst Decision
Buy
Strong Buy
Analyst Count
7
9
Target Price
★ $36.51
$23.00
AVG Volume (30 Days)
300.2K
★ 997.2K
Earning Date
10-28-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
10.26
★ 159.21
EPS
N/A
★ 1.03
Revenue
$5,636,000.00
★ $106,470,000.00
Revenue This Year
N/A
$43.81
Revenue Next Year
$1,837.59
$15.30
P/E Ratio
★ N/A
$8.83
Revenue Growth
35.77
★ 350.91
52 Week Low
$8.63
$8.01
52 Week High
$26.19
$15.04

Technical Indicators

Market Signals
Indicator
DBVT
ZVRA
Relative Strength Index (RSI) 37.71 35.83
Support Level $8.78 N/A
Resistance Level $12.41 $9.24
Average True Range (ATR) 0.76 0.66
MACD -0.12 -0.22
Stochastic Oscillator 0.97 0.86

Price Performance

Historical Comparison
DBVT
ZVRA

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

About ZVRA Zevra Therapeutics Inc.

Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

Share on Social Networks: